Dear Sir,

The Psoriasis Association welcomes this Rapid Review from NICE looking at Ustekinumab for active psoriatic arthritis and supports the recommendation that it should be recommended as an option for those contraindicated to TNF alpha inhibitors, or have had treatment with one or more TNF alpha inhibitor. We feel that these are sound and provide a suitable basis for guidance to the NHS, as offer a treatment option to people who may otherwise remain un-treated or on suboptimal therapies owing to them having exhausted other forms of treatments.

Kind regards,

[redacted]

[redacted]

www.psoriasis-association.org.uk and www.psoteen.org.uk